Azithromycin

C difficile risk
Medium
Oral Bioavailability
Moderate

Dosing

Respiratory Infection

  • Inpatient: 500mg PO/IV x 3 days

  • Outpatient: 500 mg PO x 3 days, or, 500mg PO on day 1 then 250mg daily for 4 days

General Information

  • Community acquired pneumonia

  • Pertussis

  • Upper respiratory tract infections

  • Chlamydial infections

  • Mycobacterial infections

  • Mycobacterium avium complex (MAC) prophylaxis in HIV patients

Monitor QTc in patients with increased risk

Prolongation of QTc interval. Association with increased cardiovascular mortality in observational studies.

Prolonged half life may contribute to macrolide resistance.

  • Other drugs that prolong QTc

  • Increases cyclosporine levels

  • May increase digoxin levels

  • Potential increased risk of rhabdomyolysis when used with statins

Very high tissue penetration and concentration intracellularly means in vivo activity may not be predicted by in vitro testing.

Antimicrobial class: Macrolide

Pregnancy category: B

Average serum half life: 68 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.